- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DISHMAN PHARMA - DR. DATSONS LABS
DISHMAN PHARMA vs DR. DATSONS LABS - Comparison Results
Current Valuations
| DISHMAN PHARMA | DR. DATSONS LABS | DISHMAN PHARMA/ DR. DATSONS LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | -10.9 | - | View Chart |
| P/BV | x | 3.3 | 0.2 | 2,061.5% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 DISHMAN PHARMA  DR. DATSONS LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
DR. DATSONS LABS Mar-14 |
DISHMAN PHARMA/ DR. DATSONS LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 126 | 298.1% | |
| Low | Rs | 129 | 31 | 417.2% | |
| Sales per share (Unadj.) | Rs | 197.8 | 133.0 | 148.7% | |
| Earnings per share (Unadj.) | Rs | 21.2 | 0.2 | 13,987.0% | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 6.6 | 525.5% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 128.8 | 139.7% | |
| Shares outstanding (eoy) | m | 80.69 | 31.66 | 254.9% | |
| Bonus/Rights/Conversions | - | FCCB | - | ||
| Price / Sales ratio | x | 1.3 | 0.6 | 216.2% | |
| Avg P/E ratio | x | 11.9 | 516.1 | 2.3% | |
| P/CF ratio (eoy) | x | 7.2 | 11.8 | 61.2% | |
| Price / Book Value ratio | x | 1.4 | 0.6 | 230.2% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 2,477 | 819.6% | |
| No. of employees | `000 | 0.8 | NA | - | |
| Total wages/salary | Rs m | 5,355 | 56 | 9,562.3% | |
| Avg. sales/employee | Rs Th | 19,252.7 | NM | - | |
| Avg. wages/employee | Rs Th | 6,459.5 | NM | - | |
| Avg. net profit/employee | Rs Th | 2,064.1 | NM | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 4,211 | 379.1% | |
| Other income | Rs m | 265 | 79 | 337.2% | |
| Total revenues | Rs m | 16,226 | 4,289 | 378.3% | |
| Gross profit | Rs m | 4,103 | 569 | 721.6% | |
| Depreciation | Rs m | 1,091 | 204 | 533.6% | |
| Interest | Rs m | 944 | 430 | 219.5% | |
| Profit before tax | Rs m | 2,334 | 13 | 18,374.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | -2 | -61.1% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | 6 | 10,223.0% | |
| Profit after tax | Rs m | 1,711 | 5 | 35,647.9% | |
| Gross profit margin | % | 25.7 | 13.5 | 190.4% | |
| Effective tax rate | % | 26.7 | 48.0 | 55.6% | |
| Net profit margin | % | 10.7 | 0.1 | 9,404.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 6,852 | 160.8% | |
| Current liabilities | Rs m | 9,517 | 6,711 | 141.8% | |
| Net working cap to sales | % | 9.4 | 3.3 | 280.8% | |
| Current ratio | x | 1.2 | 1.0 | 113.4% | |
| Inventory Days | Days | 110 | 161 | 68.7% | |
| Debtors Days | Days | 35 | 318 | 10.9% | |
| Net fixed assets | Rs m | 16,304 | 3,673 | 443.9% | |
| Share capital | Rs m | 161 | 317 | 51.0% | |
| "Free" reserves | Rs m | 12,907 | 3,761 | 343.2% | |
| Net worth | Rs m | 14,516 | 4,078 | 356.0% | |
| Long term debt | Rs m | 4,189 | 1,671 | 250.7% | |
| Total assets | Rs m | 29,805 | 12,633 | 235.9% | |
| Interest coverage | x | 3.5 | 1.0 | 337.1% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 70.4% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 160.7% | |
| Return on assets | % | 8.9 | 3.4 | 258.7% | |
| Return on equity | % | 11.8 | 0.1 | 10,013.7% | |
| Return on capital | % | 17.5 | 7.7 | 228.5% | |
| Exports to sales | % | 24.8 | 22.9 | 108.3% | |
| Imports to sales | % | 3.7 | 14.3 | 26.1% | |
| Exports (fob) | Rs m | 3,956 | 964 | 410.4% | |
| Imports (cif) | Rs m | 596 | 602 | 99.1% | |
| Fx inflow | Rs m | 4,952 | 964 | 513.6% | |
| Fx outflow | Rs m | 697 | 607 | 114.8% | |
| Net fx | Rs m | 4,255 | 357 | 1,192.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 1,345 | 207.2% | |
| From Investments | Rs m | -1,529 | -2,256 | 67.8% | |
| From Financial Activity | Rs m | -941 | -1,200 | 78.4% | |
| Net Cashflow | Rs m | 316 | -2,111 | -15.0% | |
Share Holding
| Indian Promoters | % | 61.4 | 4.5 | 1,355.4% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 3.7 | 0.0 | - | |
| FIIs | % | 12.7 | 1.4 | 940.7% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 22.1 | 94.1 | 23.5% | |
| Shareholders | 46,261 | 20,807 | 222.3% | ||
| Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: MERCK LTD STERLING BIOTECH ASTRAZENECA PHARMA AUROBINDO PHARMA IPCA LABS
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)
After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.
Related Views on News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)
Sep 12, 2018Is the pharma sector poised for a comeback? Is the worst over? I believe so.
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
Are You Blindly Investing In Equities? Read This...(Outside View)
Sep 11, 2018PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.
Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)
Sep 12, 2018PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA - MERCK LTD COMPARISON
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.